EODData

MEMBERSHIP REGISTER LOG IN

FRA, IMR: AC IMMUNE SA SF-02

11 Feb 2026
LAST:

2.495

CHANGE:
 0.04		OPEN:
2.495		HIGH:
2.495		ASK:
0.000		VOLUME:
4
CHG(%):
1.38		PREV:
2.530		LOW:
2.495		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Feb 262.4952.4952.4952.4954
10 Feb 262.5302.5302.5302.5304
09 Feb 262.5702.6052.5702.6054
06 Feb 262.4252.5902.4252.5009.8K
05 Feb 262.5202.6252.5002.5305.8K
04 Feb 262.7502.7502.7502.7501.7K
03 Feb 262.6902.6902.6902.6901.7K
02 Feb 262.6102.6102.6102.6100
30 Jan 262.7502.7502.7502.7501.7K
29 Jan 262.8402.8402.8402.8401.7K

PROFILE

Name:AC IMMUNE SA SF-02
About:AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Sector:Healthcare
Industry:Biotechnology
Address:Building B, Lausanne, Switzerland, 1015
Website:https://www.acimmune.com
ISIN:CH0329023102
LEI:967600VLQ0ZC2HSOG765

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.28 
Forward P/E:29.94 
PEG Ratio:29.94 
Price to Sales:62.01 
Price to Book:4.04 
Profit Margin:-1.75 
Operating Margin:-16.72 
Return on Assets:-0.22 
Return on Equity:-0.75 
Revenue:4.7M 
Shares:100.6M 
Market Cap:251.0M 

TECHNICAL INDICATORS

MA5:2.531.5%
MA10:2.635.4%
MA20:2.7811.5%
MA50:2.708.4%
MA100:2.656.2%
MA200:2.1516.1%
RSI14:35.95 
WPR14:-100.00 
MTM14:-0.52
ROC14:-0.17 
ATR:0.10 
Week High:2.7510.2%
Week Low:2.432.9%
Month High:3.2429.7%
Month Low:2.4316.1%
Year High:3.3232.9%
Year Low:1.25100.1%
Volatility:42.30